95% CI, 1.09-1.37) and dulaglutide (HR = 1.36
"I havent seen this number since 2014
The two primary markers, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), both tend to improve during treatment
Dulaglutides safety profile is consistent with other GLP-1 receptor agonists, with transient nausea being the most frequently reported adverse event (14.6% incidence). Dose escalation from 0.75 to 1.5 mg is recommended after at least four weeks, based on individual glycemic control needs [57]
The initiative offers Zepbound in a convenient multi-dose injectable form at a fixed net price of $449 per month across all doses, less than half the drugs list price of over $1,000
Monitor your levels closely and speak with your provider about lowering doses of those drugs if needed